1-20 of 1,494 results for subject:"Life insurance"
Librarians' tools
- Search time
- 0.469 seconds
- Solr query time
- 0.006 seconds
- Search query
- subject:"Life insurance"
- We searched for
- subject_t:"Life insurance" OR subject_ses:91843
Type
House
Session
More
Year
More
Department
More
Member
More
Primary member
More
Answering member
More
Legislative stage
Legislation
More
Subject
More
Publisher
Last night I delivered my annual Mansion House speech at the Financial and Professional Services Dinner at Mansion House.
In my speech, I announced a package of further reforms to unlock investment across the country, increase access to finance for growing businesses and position the UK at the forefront of financial...
Last night I delivered my annual Mansion House speech at the Financial and Professional Services Dinner at Mansion House.
In my speech, I announced a package of further reforms to unlock investment across the country, increase access to finance for growing businesses and position the UK at the forefront of financial...
My honourable friend, Rachel Reeves MP (Chancellor of the Exchequer) has today made the following statement.
Last night I delivered my annual Mansion House speech at the Financial and Professional Services Dinner at Mansion House.
In my speech, I announced a package of further reforms to unlock investment across the country, increase...
My honourable friend, Rachel Reeves MP (Chancellor of the Exchequer) has today made the following statement.
Last night I delivered my annual Mansion House speech at the Financial and Professional Services Dinner at Mansion House.
In my speech, I announced a package of further reforms to unlock investment across the country, increase...
Letter dated 12/11/2025 from Graeme Reynolds, Director, Competition and Interim Director, Insurance, Financial Conduct Authority to Brian Leishman MP in response to a Written Question regarding the conduct of C Mutual Ltd and Maiden Life Försäkrings in the context of the removal of the Family Protection Plan. 3p.
Letter dated 12/11/2025 from Graeme Reynolds, Director, Competition and Interim Director, Insurance, Financial Conduct Authority to Brian Leishman MP in response to a Written Question regarding the conduct of C Mutual Ltd and Maiden Life Försäkrings in the context of the removal of the Family Protection Plan. 3p.
To ask the Chancellor of the Exchequer, what regulatory safeguards are in place to protect consumers from excessive premium increases following the transfer of life insurance policy liabilities.
To ask the Chancellor of the Exchequer, what regulatory safeguards are in place to protect consumers from excessive premium increases following the transfer of life insurance policy liabilities.
Insurers make commercial decisions about the pricing of insurance policies following an assessment of the relevant risks. However, the Government expects that insurers deliver good outcomes to consumers and firms are required to do so under Financial Conduct Authority (FCA) rules.
These rules require firms to ensure their products offer fair value. This means the price paid by consumers must be reasonable compared to the benefits they receive. The FCA monitors firms and has robust powers to act against firms that breach its rules.
The FCA and the Prudential Regulation Authority review the terms of transfers of business between insurance providers to ensure an appropriate degree of consumer protection, and the views of both regulators are considered by the Courts as part of the transfer process. The FCA would, for example, expect to see evidence that policyholders would not be adversely affected by any changes to the way their policies will be administered (including with respect to pricing) after a transfer.
To ask the Chancellor of the Exchequer, what steps her Department is taking to regulate the pricing of legacy life insurance policies following provider transfers.
To ask the Chancellor of the Exchequer, what steps her Department is taking to regulate the pricing of legacy life insurance policies following provider transfers.
Insurers make commercial decisions about the pricing of insurance policies following an assessment of the relevant risks. However, the Government expects that insurers deliver good outcomes to consumers and firms are required to do so under Financial Conduct Authority (FCA) rules.
These rules require firms to ensure their products offer fair value. This means the price paid by consumers must be reasonable compared to the benefits they receive. The FCA monitors firms and has robust powers to act against firms that breach its rules.
The FCA and the Prudential Regulation Authority review the terms of transfers of business between insurance providers to ensure an appropriate degree of consumer protection, and the views of both regulators are considered by the Courts as part of the transfer process. The FCA would, for example, expect to see evidence that policyholders would not be adversely affected by any changes to the way their policies will be administered (including with respect to pricing) after a transfer.
My Lords, as reported to the other place, this Government are determined to reinvigorate the UK’s capital markets to drive growth and investment. These regulations form part of that commitment by implementing a smooth transition to the reformed Solvency II regime, which governs the rules that maintain the safety and...
My Lords, as reported to the other place, this Government are determined to reinvigorate the UK’s capital markets to drive growth and investment. These regulations form part of that commitment by implementing a smooth transition to the reformed Solvency II regime, which governs the rules that maintain the safety and...
My Lords, I recognise the circumstances in which these regulations have been brought forward. They are part of the Brexit dividend that we end up discussing—this carrying forward of regulations as a consequence of leaving the single European regime. I will use them as an opportunity to raise an issue...
My Lords, I recognise the circumstances in which these regulations have been brought forward. They are part of the Brexit dividend that we end up discussing—this carrying forward of regulations as a consequence of leaving the single European regime. I will use them as an opportunity to raise an issue...
My Lords, I welcome these regulations and thank the Minister for her very clear description of their use and how they will be put into practice. We on these Benches recognise the importance of this legislation in ensuring that insurance firms act safely and responsibly. The legislation also seeks to...
My Lords, I welcome these regulations and thank the Minister for her very clear description of their use and how they will be put into practice. We on these Benches recognise the importance of this legislation in ensuring that insurance firms act safely and responsibly. The legislation also seeks to...
My Lords, I thank noble Lords for their interest in this area, which is exceptionally important to putting ourselves in the best possible position to take advantage of the different agendas that the Government are moving on.
My noble friend Lord Davies was absolutely correct that I am unable to answer...
My Lords, I thank noble Lords for their interest in this area, which is exceptionally important to putting ourselves in the best possible position to take advantage of the different agendas that the Government are moving on.
My noble friend Lord Davies was absolutely correct that I am unable to answer...
Lords motion to consider. Agreed to on question.
Lords motion to consider. Agreed to on question.
That this House expresses concern following reports of those with life insurance premiums with Aviva being denied early pay outs on diagnosis of terminal illness due to a pernicious small print in their policy wording which requires diagnosis of a terminal illness to take place some years before the policy actually expires; notes the case of Salford resident Shaun Pinkney who was diagnosed with terminal cancer two months before his policy was due to expire but was refused his claim as his policy stated that terminal illness diagnosis must take place at least 18 months prior to the policy expiration date; further notes with concern that Aviva would not renew his policy because he had terminal cancer; recognises that Aviva has now ceased selling policies where there was a discrepancy between the end of the major benefit and the termination of the rest of the policy; further recognises that this would indicate that Aviva knows these policies are not fair, practical or fit for purpose; and calls on the Government to speak to the insurance industry and carry out a form of inquiry to see how widespread this practice was.
That this House expresses concern following reports of those with life insurance premiums with Aviva being denied early pay outs on diagnosis of terminal illness due to a pernicious small print in their policy wording which requires diagnosis of a terminal illness to take place some years before the policy...
To ask the Secretary of State for Health and Social Care, whether he has had recent discussions with providers of life insurance on the level of premiums offered to applicants who have tested negative for Huntington's disease.
To ask the Secretary of State for Health and Social Care, whether he has had recent discussions with providers of life insurance on the level of premiums offered to applicants who have tested negative for Huntington's disease.
The Code on Genetic Testing and Insurance is a shared agreement between the Government and the Association of British Insurers (ABI) on the use of genetic testing in underwriting insurance policies. Compliance with the Code, and the adoption of the Commitments in the Code, is a condition of membership for all ABI members.
The Government and the ABI launched a Call for Evidence on the Code on 25 July 2023 and closed on 17 October 2023. The Call for Evidence gathered views around how to transparently assess which predictive genetic test results may need to be disclosed under the Code in the future, as well as whether approaches used in other countries should be considered.
The ABI has recently published a revised Consumer Guide to the Code, which directly addresses concerns about the level of premiums offered to applicants who have tested negative for Huntington's disease. The consumer guide is available at the following link:
While no specific conversations have taken place with life insurance providers, the Government continues to work closely with the ABI to ensure the Code remains fit for purpose and beneficial to both consumers and the insurance industry.
To ask the Secretary of State for Health and Social Care, whether his Department has conducted research on the guidance provided to insurance companies by the governments of other European countries on requesting information about the genetic history of life insurance applicants.
To ask the Secretary of State for Health and Social Care, whether his Department has conducted research on the guidance provided to insurance companies by the governments of other European countries on requesting information about the genetic history of life insurance applicants.
The Code on Genetic Testing and Insurance is a shared agreement between the Government and the Association of British Insurers (ABI) on the use of genetic testing in underwriting insurance policies. Compliance with the Code, and the adoption of the Commitments in the Code, is a condition of membership for all ABI members.
The Government and the ABI launched a Call for Evidence on the Code on 25 July 2023 and closed on 17 October 2023. The Call for Evidence gathered views around how to transparently assess which predictive genetic test results may need to be disclosed under the Code in the future, as well as whether approaches used in other countries should be considered.
The ABI has recently published a revised Consumer Guide to the Code, which directly addresses concerns about the level of premiums offered to applicants who have tested negative for Huntington's disease. The consumer guide is available at the following link:
While no specific conversations have taken place with life insurance providers, the Government continues to work closely with the ABI to ensure the Code remains fit for purpose and beneficial to both consumers and the insurance industry.
To ask the Secretary of State for Health and Social Care, whether his Department made an assessment of the potential merits of including references to conditions other than Huntington’s disease in the code on genetic testing and insurance.
To ask the Secretary of State for Health and Social Care, whether his Department made an assessment of the potential merits of including references to conditions other than Huntington’s disease in the code on genetic testing and insurance.
The Code on Genetic Testing and Insurance is a shared agreement between the Government and the Association of British Insurers (ABI) on the use of genetic testing in underwriting insurance policies. Compliance with the Code, and the adoption of the Commitments in the Code, is a condition of membership for all ABI members.
The Government and the ABI launched a Call for Evidence on the Code on 25 July 2023 and closed on 17 October 2023. The Call for Evidence gathered views around how to transparently assess which predictive genetic test results may need to be disclosed under the Code in the future, as well as whether approaches used in other countries should be considered.
The ABI has recently published a revised Consumer Guide to the Code, which directly addresses concerns about the level of premiums offered to applicants who have tested negative for Huntington's disease. The consumer guide is available at the following link:
While no specific conversations have taken place with life insurance providers, the Government continues to work closely with the ABI to ensure the Code remains fit for purpose and beneficial to both consumers and the insurance industry.
(Except clauses 5 and 6, 7 to 9, 10 to 15, schedule 1, clauses 18 to 25, 27, 47, 48, 50 to 60, schedules 7 to 9, clauses 121 to 264, schedules 14 to 17, clauses 265 to 277, schedule 18, clauses 278 to 312 and any new clauses or new schedules relating to the subject matter of those clauses and schedules.) Programme motion agreed to. Written evidence motion agreed to. Clauses 1 to 4, 16, 17 26, and 28 to 35 agreed to. Schedule 3 agreed to.
(Except clauses 5 and 6, 7 to 9, 10 to 15, schedule 1, clauses 18 to 25, 27, 47, 48, 50 to 60, schedules 7 to 9, clauses 121 to 264, schedules 14 to 17, clauses 265 to 277, schedule 18, clauses 278 to 312 and any new clauses or...